Patents Assigned to Institute for Cancer Research
-
Patent number: 11970469Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.Type: GrantFiled: June 3, 2019Date of Patent: April 30, 2024Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITALInventors: Terrence Rabbitts, Camilo Quevedo, Carole Bataille
-
Publication number: 20240131070Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: December 11, 2023Publication date: April 25, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.Inventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
-
Publication number: 20240123069Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.Type: ApplicationFiled: December 11, 2023Publication date: April 18, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Zeda Zhang
-
Patent number: 11957751Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 11959136Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.Type: GrantFiled: March 7, 2022Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, LTDInventors: Chunxiao Song, Yibin Liu
-
Publication number: 20240117066Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to uPAR and methods of using such antibodies or antigen-binding fragments thereof same.Type: ApplicationFiled: December 11, 2023Publication date: April 11, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute For Cancer Research, Memorial Hospital For Cancer and Allied DiseasesInventors: Scott W. Lowe, Michel Sadelain, Corina Amor Vegas
-
Patent number: 11946043Abstract: The present disclosure provides methods for selectively tagging 5-methylcytosine in a DNA sample and using this approach for genome-wide profiling of 5-methylcytosine in a low input DNA sample such as circulating cell-free DNA.Type: GrantFiled: September 11, 2018Date of Patent: April 2, 2024Assignee: Ludwig Institute for Cancer Research LtdInventors: Chunxiao Song, Paulina Siejka
-
Patent number: 11944319Abstract: The present disclosure provides surgical clamps. The clamp has a body with a mouth that opens and closes to permit the body to encircle a bundle of tissue containing a blood vessel which a surgeon wishes to occlude. The clamp also has an articulating arm that rotates on a hinge and passes through apertures of the clamp body. The apertures and/or the articulating arm include ratchet components that permit the surgeon to apply dynamic adjustable tensioning to the tissue and vessel in real time. This dynamic tension permits a surgeon to ensure a specific reduction of blood flow through the vessel.Type: GrantFiled: February 12, 2019Date of Patent: April 2, 2024Assignee: Institute For Cancer ResearchInventors: Benjamin T. Ristau, Robert G. Uzzo
-
Publication number: 20240050486Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.Type: ApplicationFiled: July 7, 2023Publication date: February 15, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied DiseasesInventors: Lorenz Studer, Gabriele CICERI
-
Publication number: 20240050385Abstract: The present disclosure relates to the use of iron chelation to prevent and/or treat leptomeningeal metastasis. In certain embodiments, the present disclosure provides methods for the prevention and/or treatment of leptomeningeal metastasis that include the administration of an iron chelator to a subject. The present disclosure further provides kits for performing such methods.Type: ApplicationFiled: January 17, 2023Publication date: February 15, 2024Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Adrienne Boire, Yudan Chi
-
Publication number: 20240052420Abstract: The present invention provides a method for predicting whether a human subject having breast cancer will be resistant to, or sensitive to, therapy with a cyclin-dependent kinase (CDK) inhibitor, the method comprising: a) measuring the gene expression in a sample obtained from the breast tumour of the patient to obtain a sample gene expression profile of at least the following modules: (i) a luminal vs.Type: ApplicationFiled: September 24, 2021Publication date: February 15, 2024Applicants: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology Limited, Breast Cancer NowInventors: Mitchell Dowsett, Eugene Francis Schuster, Chon U Maggie Cheang
-
Patent number: 11897962Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: August 21, 2020Date of Patent: February 13, 2024Assignees: AGENUS INC., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20240016957Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.Type: ApplicationFiled: July 25, 2023Publication date: January 18, 2024Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer CenterInventor: Kerry S. Campbell
-
Publication number: 20240018600Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.Type: ApplicationFiled: November 14, 2022Publication date: January 18, 2024Applicants: Ontario Institute for Cancer Research (OICR), UNIVERSITY HEALTH NETWORKInventors: Julia A. HOPKINS, Paul Boutros, Robert G. BRISTOW
-
Patent number: 11859183Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.Type: GrantFiled: May 10, 2021Date of Patent: January 2, 2024Assignee: Institute For Cancer ResearchInventors: Amriti R. Lulla, Wafik S. El-Deiry
-
Publication number: 20230414660Abstract: The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.Type: ApplicationFiled: November 12, 2021Publication date: December 28, 2023Applicants: Ludwig Institute for Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, University of LausanneInventors: George Coukos, Melita Irving, Vincent Zoete
-
Patent number: 11833168Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).Type: GrantFiled: June 14, 2019Date of Patent: December 5, 2023Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer ResearchInventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
-
Publication number: 20230381315Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule); and a gene disruption of a CD70 locus. The gene disruption of the CD70 locus can improve the activity and/or efficiency of the cells.Type: ApplicationFiled: April 25, 2023Publication date: November 30, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASESInventors: Michel Sadelain, Jorge Mansilla-Soto, Sacha P. Haubner
-
Publication number: 20230372551Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.Type: ApplicationFiled: September 21, 2021Publication date: November 23, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES, PHLIP, INC.Inventors: Jason S. LEWIS, Yana K. RESHETNYAK, Lukas M. CARTER, David BAUER
-
Publication number: 20230364276Abstract: Provided herein is a one-step method for chelating actinium-225 to a construct comprising a chelator linked to a biomolecule, such as, an antibody or monoclonal antibody, via a bifunctional ligand in, for example, a 3-arm configuration. Also provided are methods for increasing the radiochemical yield of an actinium-225-chelant-biomolecule complex and for producing a high specific activity actinium-225 complex. The chelation is performed at a physiological temperature, about 37° C. Also provided are high specific activity actinium-225 complexes, that is, actinium-225 chelated to the chelator-biomolecule construct and pharmaceutical compositions thereof. Further provided are methods of treating a neoplastic disease or disorder with the actinium-225 complexes.Type: ApplicationFiled: April 24, 2023Publication date: November 16, 2023Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Peter M. Smith-Jones, Michael R. McDevitt, William F. Maguire